Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cipralisant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cipralisant SCHEMBL7069804 | 1.00 | HRH3 (0.57) | HRH3 | |
| Cipralisant SCHEMBL8395048 | 1.00 | HRH3 (0.57) | HRH3 | |
| SCHEMBL8397428 | 0.81 | HRH3 (0.37) | HRH3 | |
| SCHEMBL8395186 | 0.80 | HRH3 (0.36) | HRH3 | |
| SCHEMBL8397521 | 0.79 | HRH3 (0.36) | HRH3 | |
| SCHEMBL8397507 | 0.74 | HRH3 (0.33) | HRH3 | |
| Cipralisant SCHEMBL1649825 | 0.73 | HRH3 (1.00) | HRH3 | |
| SCHEMBL8314636 | 0.73 | HRH3 (0.30) | HRH3 | |
| SCHEMBL6136538 | 0.70 | — | — | |
| SCHEMBL18998463 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | GLIATECH, INC. | 2003-04-10 | — | — | US | disclosed |
| US-6008240-A | AN ANTAGONIST OF HISTAMINE H3 RECEPTORS; FOR TREATING ALLERGY, INFLAMMATION, CARDIOVASCULAR DISEASE (HYPER OR HYPOTENSION), GASTROINTESTINAL DISORDERS, CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS | GLIATECH, INC. (US) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | HRH3, HRH4, HRH2 | HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.